Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer.Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018.

Biotechnology

Health Care

Therapeutics

Mercy BioAnalytics, Inc.

Mercy BioAnalytics, Inc.'s headquarters in Natick, MA, United States

Dawn Mattoon

Darrin Crisitello

Toumy G.

Michael Smith

Diane Marcou

The Research and Development team at Mercy BioAnalytics focuses on advancing the company's innovative approach to cancer detection through the study and application of extracellular vesicles (EVs). This multidisciplinary team, comprising scientists and researchers, conducts experiments, analyzes data, and develops new methodologies to enhance the sensitivity and specificity of early-stage cancer diagnostics. Their collaborative efforts aim to translate cutting-edge scientific discoveries into practical solutions that can improve patient outcomes in the fight against cancer.

Research and Development

The Leadership Team at Mercy BioAnalytics, Inc. is responsible for setting the strategic direction and overseeing the overall operations of the company. This team drives innovation in the development of early cancer detection technologies using extracellular vesicles, ensuring compliance with regulatory standards, and managing clinical programs. They collaborate to align business objectives with scientific advancements, fostering a culture of excellence and dedication to improving patient outcomes.

Mercy BioAnalytics, Inc.

Org chart

Teams

Research and Development

Leadership Team

Offices

Mercy BioAnalytics, Inc.

Org chart

Teams

Research and Development

Leadership Team

Offices

Related companies